MRC Epidemiology Unit
A new study led by Dr Marie Spreckley is exploring the lived experiences of people using next-generation weight management medications. AMPLIFY (Amplifying Meaningful Perspectives and Lived experiences of Incretin therapy use From diverse communitY voices) aims to bring the voices of patients to the forefront of research and inform future clinical and public-health practice.
Incretin-based medicines such as semaglutide and tirzepatide are transforming obesity care. However, while clinical trials show significant weight-loss outcomes, far less is known about how people experience these treatments, including how they manage changes in eating behaviour, wellbeing, and daily life.
Understanding these experiences will be particularly important for identifying the kinds of information and support that could help people use these treatments safely and sustainably.
AMPLIFY will focus on gathering insights from adults across diverse communities in the UK. This will include people who have been prescribed weight management medications in NHS or private settings, as well as those who have chosen to stop treatment. By prioritising patient and public involvement at every stage, the study aims to capture a wide range of perspectives, especially from groups whose voices are often under-represented in obesity research.
Supported by the University of Cambridge Public Engagement Starter Fund, AMPLIFY will be co-designed with partners from Obesity Voices, a national network of patients and members of public with lived experience of obesity. The project will convene a series of focus groups to explore how people experience these therapies beyond weight loss.
Dr Spreckley said:
AMPLIFY is about ensuring that patients’ voices inform how next-generation weight management medications are used and supported. By understanding the real-world experiences of people from different communities, we can help shape services that are equitable, effective, and responsive to their needs.”
Insights will be shared in co-authored qualitative papers, a reflective report, and a plain-language summary, and will be presented at the 2027 Cambridge Festival. These activities will help ensure that lived-experience voices shape future research priorities and clinical guidance.
AMPLIFY reflects the MRC Epidemiology Unit’s commitment to patient-centred research and to addressing health inequalities in obesity care. The insights from AMPLIFY aim to inform guidance and wrap-around care models for people using weight management medications. By highlighting the challenges and opportunities identified by patients, the study aims to support clinicians, policy-makers and service providers to ensure these new treatments deliver not only weight-loss benefits, but also improvements in overall health and quality of life.